Israel Englander Immuno Gen, Inc. Call Options Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $270,382 - $649,915	-21,700 Reduced 21.7%	78,300 $2.32 Million
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $2.04 Million - $10.9 Million	-544,500 Reduced 84.48%	100,000 $1.89 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $1.26 Million - $1.69 Million	344,500 Added 114.83%	644,500 $2.48 Million
Q4 2022 Feb 14, 2023	SELL	$4.55 - $6.31 $1.39 Million - $1.92 Million	-305,000 Reduced 50.41%	300,000 $1.49 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $1.81 Million - $2.62 Million	405,000 Added 202.5%	605,000 $2.89 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.